Literature DB >> 2902382

Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylprednisolone.

J B Bell1, B C Millar, J A Maitland, A Nandi, M Gore, T J McElwain.   

Abstract

The relation between clonogenic myeloma cells, assayed in vitro, and clinical status was studied in 20 patients with multiple myeloma before and after VAMP therapy (vincristine, doxorubicin, and methylprednisolone). 14 patients showed an improvement in clinical status, as judged by a fall in myeloma protein and a decrease in plasmacytoid myeloma cell infiltration in the bone marrow. However, in 11 of these 14, there was an increase in the number of clonogenic myeloma cells. This suggests that the treatment changed the myeloma cell population in the residual bone marrow. To be effective, subsequent chemotherapy should be aimed at destroying this population of myeloma cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902382     DOI: 10.1016/s0140-6736(88)92599-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  2 in total

1.  Repeat administration of high dose melphalan in relapsed myeloma.

Authors:  J L Mansi; D Cunningham; C Viner; E Ellis; M Meldrum; S Milan; M Gore
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

2.  Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.

Authors:  J A Maitland; B C Millar; J B Bell; A Montes; J Treleaven; M E Gore; T J McElwain
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.